Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function

European Journal of Clinical Pharmacology

Volumn 73, Issue 3, 2017, Pages 333-342

  Usman, Muhammad ^a,b   Frey, Otto R ^c   Hempel, Georg ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF VETERINARY AND ANIMAL SCIENCES   (Pakistan)

^c Hospital of Heidenheim   (Germany)

Author keywords

Elderly; Meropenem; NONMEM ; Population pharmacokinetics; Simulations

Indexed keywords

MEROPENEM; ANTIINFECTIVE AGENT; THIENAMYCIN DERIVATIVE;

ADULT; AGED; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CONTINUOUS INFUSION; CREATININE CLEARANCE; DRUG DOSE REGIMEN; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; SIMULATION; STEADY STATE; BLOOD; KIDNEY FUNCTION TEST; MONTE CARLO METHOD; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MONTE CARLO METHOD; THIENAMYCINS;

EID: 85003845834     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-016-2172-4     Document Type: Article

References (44)

1. Wiseman LR et al (1995) Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50(1):73–101
2. Spellberg B et al (2011) Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis 52(Suppl 5):S397–S428
3. Boucher HW et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48(1):1–12
4. Wittau, M., et al. 2015. Population pharmacokinetics and target attainment of meropenem in plasma and tissue of morbidly obese patients after laparoscopic intraperitoneal surgery. Antimicrob Agents Chemother
5. Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26(1):1–10 quiz 11-2
6. Nicolau DP (2008) Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis 47(Suppl 1):S32–S40
7. Shekar K et al (2014) The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Crit Care 18(6):565
8. Li C et al (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51(5):1725–1730
9. De Waele JJ et al (2014) Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med 40(3):380–387
10. Ulldemolins, M., et al. 2015 Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. Antimicrob Agents Chemother
11. Mouton JW, van den Anker JN (1995) Meropenem clinical pharmacokinetics. Clin Pharmacokinet 28(4):275–286
12. Udy AA et al (2012) Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142(1):30–39
13. Taccone FS et al (2010) Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14(4):R126
14. Varghese JM, Roberts JA, Lipman J (2011) Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin 27(1):19–34
15. Taccone FS et al (2011) Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock. Curr Infect Dis Rep 13(5):406–415
16. Blanchet B et al (2008) Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 47(10):635–654
17. Beumier M et al (2015) Elevated beta-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol 81(5):497–506
18. Verhave JC et al (2005) Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 46(2):233–241
19. Jaruratanasirikul S et al (2015) Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother 59(6):2995–3001
20. Goncalves-Pereira J et al (2014) Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients. BMC Pharmacol Toxicol 15:21
21. Ramon-Lopez A et al (2015) Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations. J Antimicrob Chemother 70(3):882–890
22. Doh K et al (2010) Population pharmacokinetics of meropenem in burn patients. J Antimicrob Chemother 65(11):2428–2435
23. Isla A et al (2008) Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet 47(3):173–180
24. Jamal JA et al (2015) Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents 45(1):41–45
25. Kees, M.G., et al. 2015 Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients. J Clin Pharmacol
26. Alobaid, A.S., et al. 2015 What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients? J Antimicrob Chemother
27. Bias M, Frey O, Köberer A (2010) HPLC-Methode zur quantitativen Bestimmung von Meropenem im Serum. Krankenhauspharmazie 31(11):482–485
28. Lindbom L, Pihlgren P, Jonsson EN (2005) PsN-toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Prog Biomed 79(3):241–257
29. Keizer RJ et al (2011) Pirana and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Prog Biomed 101(1):72–79
30. European Committee of Antimicrobial Susceptibility testing (EUCAST) 2016 Clinical breakpoints. [cited 2016 28 Feb 2016]; Available from: http://www.eucast.org/clinical_breakpoints
31. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41
32. Devine BJ (1974) Gentamicin therapy. Drug Intell Clin Pharm 8:650–655
33. Zhou QT et al (2011) Pharmacokinetics and pharmacodynamics of meropenem in elderly chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study. Drugs Aging 28(11):903–912
34. Krueger WA et al (2005) Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 49(5):1881–1889
35. Roberts JA et al (2009) Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64(1):142–150
36. Lodise TP et al (2007) Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J Antimicrob Chemother 60(5):1038–1044
37. Li C et al (2006) Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46(10):1171–1178
38. Ariano RE et al (2005) Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 39(1):32–38
39. Christensson BA et al (1992) Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 36(7):1532–1537
40. Ikawa K et al (2010) Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients. J Infect Chemother 16(2):139–143
41. Shino N et al (2015) Development and assessment of a nomogram to propose the initial dosage regimen of a meropenem infusion based on serum creatinine and age using a Monte Carlo simulation. Chem Pharm Bull (Tokyo) 63(12):986–991
42. Frippiat F et al (2015) Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother 70(1):207–216
43. Lorente L et al (2006) Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 40(2):219–223
44. Berthoin K et al (2010) Stability of meropenem and doripenem solutions for administration by continuous infusion. J Antimicrob Chemother 65(5):1073–1075